Skip to main content

Kayexalate (sodium polystyrene sulfonate) Disease Interactions

There are 3 disease interactions with Kayexalate (sodium polystyrene sulfonate):

Major

Sodium polystyrene sulfonate (applies to Kayexalate) hypokalemia

Major Potential Hazard, High plausibility.

The use of sodium polystyrene sulfonate is contraindicated in patients with hypokalemia. Serious potassium deficiency can occur from therapy with sodium polystyrene sulfonate. Sodium polystyrene sulfonate exchanges sodium ions for potassium ions in the intestine or colon. Monitoring serum potassium levels carefully and evaluating the patient's clinical condition and electrocardiogram may be necessary.

References

  1. "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals, New York, NY.
  2. Meyer I "Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia." ANNA J 20 (1993): 93-5
Major

Sodium polystyrene sulfonate (applies to Kayexalate) obstructive bowel disease

Major Potential Hazard, Moderate plausibility. Applicable conditions: Intestinal Obstruction

The use of sodium polystyrene sulfonate is contraindicated in patients with obstructive bowel disease. Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. Therapy with this agent should be avoided in patients who have not had a bowel movement post-surgery, and patients who are at risk of developing constipation or impaction. Therapy with sodium polystyrene sulfonate should be discontinued in patients who develop constipation during treatment.

Major

Sodium polystyrene sulfonate (applies to Kayexalate) sodium load

Major Potential Hazard, Moderate plausibility. Applicable conditions: Hypertension, Congestive Heart Failure, Fluid Retention

The use of sodium polystyrene sulfonate is associated with an elevation in sodium. Therapy with sodium polystyrene sulfonate should be administered cautiously in patients with conditions that might be exacerbated by additional sodium such as severe congestive heart failure, severe hypertension, or marked edema. Compensatory restriction of sodium intake from other sources may be indicated.

References

  1. Meyer I "Sodium polystyrene sulfonate: a cation exchange resin used in treating hyperkalemia." ANNA J 20 (1993): 93-5
  2. "Product Information. Kayexalate (sodium polystyrene sulfonate)." Sanofi Winthrop Pharmaceuticals, New York, NY.

Kayexalate (sodium polystyrene sulfonate) drug interactions

There are 97 drug interactions with Kayexalate (sodium polystyrene sulfonate)

Kayexalate (sodium polystyrene sulfonate) alcohol/food interactions

There are 3 alcohol/food interactions with Kayexalate (sodium polystyrene sulfonate)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.